Literature DB >> 8282780

Effect of nonprotective vaccination on antibody response to subsequent human immunodeficiency virus infection.

S H Pincus1, K G Messer, S L Hu.   

Abstract

We have investigated the systemic anti-HIV antibody response in chimpanzees who were immunized with live vaccinia containing either the HIV envelope glycoprotein (gp160IIIB) or a control antigen (herpes simplex virus glycoprotein D) and then challenged with either a high dose (300,000 TCID50) or low dose (100 TCID50) of HIVIIIB. HIV was subsequently isolated from all animals, indicating failure of the vaccination to protect against HIV infection. Serum antibody responses were evaluated before immunization, at the time of challenge with HIV, and at multiple time points in the 9 mo after challenge. Immunization resulted in a more rapid rise of antibody to gp160 in both high and low dose animals. Antibodies to the V3 loop induced upon infection were unaffected by immunization. In low dose animals, neutralizing antibody rose more rapidly and to higher levels in the immunized animals as compared with the control. There was no difference in neutralizing antibodies between immunized and control chimpanzees in the high dose group. Epitope mapping of the anti-gp 160 response indicated that immunization with gp160 vaccinia induced a postinfection antibody response to a region of gp41 (amino acids 718-743) that was not immunogenic in control-vaccinated animals. These data indicate that failed vaccination with the HIV envelope can alter both the timing and epitope specificity of the subsequent anti-HIV antibody response. These studies also define the evolution and fine specificity of the antibody response during the critical period immediately postinfection.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8282780      PMCID: PMC293746          DOI: 10.1172/JCI116937

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  27 in total

1.  Protection of chimpanzees from infection by HIV-1 after vaccination with recombinant glycoprotein gp120 but not gp160.

Authors:  P W Berman; T J Gregory; L Riddle; G R Nakamura; M A Champe; J P Porter; F M Wurm; R D Hershberg; E K Cobb; J W Eichberg
Journal:  Nature       Date:  1990-06-14       Impact factor: 49.962

2.  Expression of AIDS virus envelope gene in recombinant vaccinia viruses.

Authors:  S L Hu; S G Kosowski; J M Dalrymple
Journal:  Nature       Date:  1986 Apr 10-16       Impact factor: 49.962

3.  Vaccine protection of chimpanzees against challenge with HIV-1-infected peripheral blood mononuclear cells.

Authors:  P N Fultz; P Nara; F Barre-Sinoussi; A Chaput; M L Greenberg; E Muchmore; M P Kieny; M Girard
Journal:  Science       Date:  1992-06-19       Impact factor: 47.728

4.  Differences in the antibody response to human immunodeficiency virus-1 envelope glycoprotein (gp160) in infected laboratory workers and vaccinees.

Authors:  S H Pincus; K G Messer; D H Schwartz; G K Lewis; B S Graham; W A Blattner; G Fisher
Journal:  J Clin Invest       Date:  1993-05       Impact factor: 14.808

5.  Augmentation of human immunodeficiency virus type 1 neutralizing antibody by priming with gp160 recombinant vaccinia and boosting with rgp160 in vaccinia-naive adults. The NIAID AIDS Vaccine Clinical Trials Network.

Authors:  B S Graham; T J Matthews; R B Belshe; M L Clements; R Dolin; P F Wright; G J Gorse; D H Schwartz; M C Keefer; D P Bolognesi
Journal:  J Infect Dis       Date:  1993-03       Impact factor: 5.226

6.  Immunization of chimpanzees confers protection against challenge with human immunodeficiency virus.

Authors:  M Girard; M P Kieny; A Pinter; F Barre-Sinoussi; P Nara; H Kolbe; K Kusumi; A Chaput; T Reinhart; E Muchmore
Journal:  Proc Natl Acad Sci U S A       Date:  1991-01-15       Impact factor: 11.205

7.  The safety and immunogenicity of a human immunodeficiency virus type 1 (HIV-1) recombinant gp160 candidate vaccine in humans. NIAID AIDS Vaccine Clinical Trials Network.

Authors:  R Dolin; B S Graham; S B Greenberg; C O Tacket; R B Belshe; K Midthun; M L Clements; G J Gorse; B W Horgan; R L Atmar
Journal:  Ann Intern Med       Date:  1991-01-15       Impact factor: 25.391

8.  Use of a new CD4-positive HeLa cell clone for direct quantitation of infectious human immunodeficiency virus from blood cells of AIDS patients.

Authors:  B Chesebro; K Wehrly; J Metcalf; D E Griffin
Journal:  J Infect Dis       Date:  1991-01       Impact factor: 5.226

9.  Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine.

Authors:  J Wintsch; C L Chaignat; D G Braun; M Jeannet; H Stalder; S Abrignani; D Montagna; F Clavijo; P Moret; J M Dayer
Journal:  J Infect Dis       Date:  1991-02       Impact factor: 5.226

10.  Principal neutralizing domain of the human immunodeficiency virus type 1 envelope protein.

Authors:  K Javaherian; A J Langlois; C McDanal; K L Ross; L I Eckler; C L Jellis; A T Profy; J R Rusche; D P Bolognesi; S D Putney
Journal:  Proc Natl Acad Sci U S A       Date:  1989-09       Impact factor: 11.205

View more
  3 in total

1.  Temporal analysis of the antibody response to HIV envelope protein in HIV-infected laboratory workers.

Authors:  S H Pincus; K G Messer; P L Nara; W A Blattner; G Colclough; M Reitz
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

2.  Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus.

Authors:  S H Pincus; R Cole; R Ireland; F McAtee; R Fujisawa; J Portis
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

3.  Microarray profiling of antibody responses against simian-human immunodeficiency virus: postchallenge convergence of reactivities independent of host histocompatibility type and vaccine regimen.

Authors:  Henry E Neuman de Vegvar; Rama Rao Amara; Lawrence Steinman; Paul J Utz; Harriet L Robinson; William H Robinson
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.